Biomedical Engineering Reference
In-Depth Information
(A)
VLDL apoB
(B)
Fig. 3
ApoC-III as an independent risk factor for coronary heart disease. Multivariate analysis
of apoC-III in VLDL and LDL (Panel A) and apoB lipoproteins with or without apoC-III (Panel
B) to risk of recurrent coronary events in the CARE trial. (A) VLDL-apoB concentration, apoC-
III concentration in VLDL+LDL, VLDL and LDL cholesterol concentrations in quintiles (Q1-
Q5) were included together in multiple logistic regression model, along with HDL-cholesterol
and plasma triglycerides. Other covariates were age, smoking, hypertension, and let ventricular
ejection fraction. (B) Relative risk of apoB concentration in VLDL and LDL with (CIII+) or
without apoC-III (CIII-) for 4th versus 1st quartile, were included together in multiple logistic
regression model, along with treatment group (pravastatin or placebo), risk factors, LDL
cholesterol, HDL cholesterol, and triglycerides. Reproduced from Sacks
et al.
(2000) (Panel A)
and Lee
et al.
(2003) (Panel B), with permission.
